



Institut luxembourgeois de la normalisation  
de l'accréditation, de la sécurité et qualité  
des produits et services

## ILNAS-EN 50527-2-3:2021

### **Procedure for the assessment of the exposure to electromagnetic fields of workers bearing active implantable medical devices - Part 2-3: Specific**

Procédure pour l'évaluation de  
l'exposition des travailleurs porteurs de  
dispositifs médicaux implantables actifs  
aux champs électromagnétiques - Partie

Verfahren zur Beurteilung der Exposition  
von Arbeitnehmern mit aktiven  
implantierbaren medizinischen Geräten  
gegenüber elektromagnetischen Feldern

## National Foreword

This European Standard EN 50527-2-3:2021 was adopted as Luxembourgish Standard ILNAS-EN 50527-2-3:2021.

Every interested party, which is member of an organization based in Luxembourg, can participate for FREE in the development of Luxembourgish (ILNAS), European (CEN, CENELEC) and International (ISO, IEC) standards:

- Participate in the design of standards
- Foresee future developments
- Participate in technical committee meetings

<https://portail-qualite.public.lu/fr/normes-normalisation/participer-normalisation.html>

### THIS PUBLICATION IS COPYRIGHT PROTECTED

Nothing from this publication may be reproduced or utilized in any form or by any mean - electronic, mechanical, photocopying or any other data carries without prior permission!

## English Version

**Procedure for the assessment of the exposure to  
electromagnetic fields of workers bearing active implantable  
medical devices - Part 2-3: Specific assessment for workers with  
implantable neurostimulators**

Procédure pour l'évaluation de l'exposition des travailleurs porteurs de dispositifs médicaux implantables actifs aux champs électromagnétiques - Partie 2-3 : Evaluation spécifique aux travailleurs porteurs de neurostimulateurs implantés

Verfahren zur Beurteilung der Exposition von Arbeitnehmern mit aktiven implantierbaren medizinischen Geräten gegenüber elektromagnetischen Feldern - Teil 2-3: Besondere Beurteilung für Arbeitnehmer mit implantierbaren Neurostimulatoren

This European Standard was approved by CENELEC on 2021-08-09. CENELEC members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration.

Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CENELEC member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CENELEC member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CENELEC members are the national electrotechnical committees of Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.



European Committee for Electrotechnical Standardization  
Comité Européen de Normalisation Electrotechnique  
Europäisches Komitee für Elektrotechnische Normung

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

## Contents

|  | Page      |
|--|-----------|
| <b>European foreword.....</b>  | <b>6</b>  |
| <b>1 Scope .....</b>   | <b>7</b>  |
| <b>2 Normative references .....</b>  | <b>7</b>  |
| <b>3 Terms and definitions .....</b>   | <b>7</b>  |
| <b>4 Specific assessment .....</b>   | <b>9</b>  |
| 4.1 Overview of specific assessments.....  | 9         |
| 4.1.1 Relation to OH&S Management Systems.....   | 9         |
| 4.1.2 Description of the assessment process .....  | 9         |
| 4.2 Specific assessment phase 0: Exclusion based on history and physician warnings .....       | 12        |
| 4.3 Specific assessment phase 1: Consideration of equipment and SCS therapy type .....         | 13        |
| 4.4 Specific assessment phase 2a – workplace EMF compared to Action Levels .....               | 15        |
| 4.5 Overview of specific assessment phases 2b and 2c .....                                     | 17        |
| 4.6 Methodology for assessment of unintended nerve stimulation and tissue damage risk .....    | 18        |
| 4.6.1 General .....  | 18        |
| 4.6.2 Overview of the assessment method given in Annexes D and E .....                         | 18        |
| 4.6.3 Selection of device parameters for assessment.....                                       | 19        |
| 4.6.4 Assessment levels for electric and magnetic fields .....                                 | 19        |
| 4.6.5 NSR and TDR calculation results for unipolar and bipolar configurations.....             | 23        |
| 4.6.6 Phase 2a risk assessment summary .....   | 26        |
| 4.7 Specific Assessment phase 2b – workplace EMF compared to NSR / TDR EMF threshold<br>levels | 27        |
| 4.7.1 Phase 2b general approach.....   | 27        |
| 4.7.2 EMF threshold zones .....  | 27        |
| 4.7.3 Conversion of EMF values.....  | 29        |
| 4.7.4 Phase 2b assessment procedure .....  | 29        |
| 4.8 Specific assessment phase 2c – adjustments for known lead characteristics .....            | 39        |
| 4.8.1 Phase 2c general approach.....   | 39        |
| 4.8.2 Phase 2c assessment procedure .....  | 41        |
| <b>5 Documentation .....</b>   | <b>42</b> |
| <b>Annex A (normative) Device specific replacement of EN 50527-1:2016, Table 1 .....</b>       | <b>43</b> |
| <b>Annex B (informative) Rationale .....</b>   | <b>47</b> |
| B.1 Introduction .....   | 47        |
| B.2 Rationale for specific clauses of this document .....                                      | 47        |
| <b>Annex C (informative) Nerve Stimulation for SCS .....</b>                                   | <b>48</b> |
| C.1 Neurostimulation techniques .....  | 48        |
| C.2 Spinal Cord Stimulation .....  | 48        |
| <b>Annex D (informative) Selection of Conductivity Values for SCS Modelling .....</b>          | <b>54</b> |
| D.1 The use of conductivity in the standard .....  | 54        |
| D.2 Conductivity literature .....  | 54        |
| D.3 Selection of values for tissue Types .....   | 59        |
| D.4 Summary .....  | 65        |
| <b>Annex E (informative) Modelling Nerve Stimulation for SCS.....</b>                          | <b>66</b> |
| E.1 Introduction .....   | 66        |
| E.2 Internal electric field threshold for nerve stimulation .....                              | 80        |
| E.3 Avoiding damage to tissue .....  | 82        |
| E.4 Assessment of voltages and currents induced in leads .....                                 | 86        |
| E.5 Assessment of nerve stimulation from external fields .....                                 | 93        |
| E.6 Assessment of tissue damage from external fields .....                                     | 97        |
| E.7 Overall assessment .....   | 100       |

|   |            |
|---|------------|
| <b>Annex F (informative) Electrode factor for non-isotropic tissue.....</b> | <b>101</b> |
| F.1    Application to isotropic tissue .....                                | 101        |
| F.2    Application to non-isotropic tissue .....                            | 103        |
| <b>Bibliography .....</b>   | <b>105</b> |

## Figures

|  |    |
|--|----|
| Figure 1 — Overview of the assessment process .....  | 11 |
| Figure 2 — Summary of assessment exclusion criteria .....  | 12 |
| Figure 3 — Specific assessment phase 1 .....   | 14 |
| Figure 4 — Specific assessment phase 2a — Initial assessment of risk of unintended nerve stimulation or tissue damage.....                                 | 17 |
| Figure 5 — Magnetic field assessment levels as selected (also Figure E.14) .....   | 21 |
| Figure 6 — Electric field assessment levels as selected (also Figure E.16).....  | 22 |
| Figure 7 — Values of NSR for assessed electric field exposures .....   | 23 |
| Figure 8 — Values of TDR for assessed electric field exposures .....   | 24 |
| Figure 9 — Values of NSR for assessed magnetic field exposures.....  | 25 |
| Figure 10 — Values of TDR for assessed magnetic field exposures .....  | 26 |
| Figure 11 — Maximum E-field for cylindrical-type bipolar lead stimulation.....   | 31 |
| Figure 12 — Maximum E-field for paddle-type bipolar lead stimulation.....  | 32 |
| Figure 13 — Maximum B-field for bipolar single lead stimulation .....  | 33 |
| Figure 14 — Maximum B-field for bipolar two lead stimulation .....   | 34 |
| Figure 15 — Maximum E-field for unipolar lead stimulation.....   | 35 |
| Figure 16 — Maximum E-field for unipolar lead stimulation (1 MHz to 100 MHz) .....   | 36 |
| Figure 17 — Maximum B-field for unipolar lead stimulation.....   | 37 |
| Figure 18 — Maximum B-field for unipolar lead stimulation (100 MHz to 5 GHz).....  | 38 |
| Figure 19 — Specific assessment phase 2c —Re-assessment of tissue damage risk using known lead characteristics .....                                       | 40 |
| Figure C.1 — Typical implantations of spinal cord stimulation devices .....  | 49 |
| Figure C.2 — Leads and electrodes for spinal cord stimulation — Paddle leads have flat electrodes and percutaneous leads have cylindrical electrodes ..... | 50 |
| Figure C.3 — Cross section of spine showing the different regions .....  | 52 |
| Figure D.1 — Conductivity values from 1996 modelled data .....   | 55 |
| Figure D.2 — Conductivities for cerebrospinal tissues (2007 data) .....  | 57 |
| Figure D.3 — Conductivities for cerebrospinal tissues (1996 and 2009 data) .....   | 58 |
| Figure D.4 — Conductivity for fat (not infiltrated, average infiltrated, fully infiltrated) .....  | 60 |
| Figure D.5 — Cross section of spine showing the different regions .....  | 62 |
| Figure D.6 — Layers of tissue adjacent to spinal cord .....  | 63 |
| Figure D.7 — Variation of directional conductivities and their ratio with frequency and the anisotropy factor .....  | 64 |
| Figure D.8 — Values of frequency dependent parameters related to conductivity as used in Annex E.....  | 65 |
| Figure E.1 — Simplified linear circuit model for isolated patch of excitable membrane. From Reilly 1998. ....  | 67 |
| Figure E.2 — Calculated strength-duration relationship for square-wave mono-phasic current pulse. From Reilly 1998. ....                                   | 68 |
| Figure E.3 — Representation of myelinated nerve .....  | 69 |
| Figure E.4 — Electric model for linear cable. From Reilly 1998. ....   | 69 |

|   |    |
|---|----|
| Figure E.5 — Equivalent circuit models for excitable membranes. From Reilly 1998.   | 70 |
| Figure E.6 — Strength-duration curves for myelinated nerve model with mono-phasic stimuli. Point electrodes within an infinite homogeneous medium | 72 |
| Figure E.7 — Illustration of the effect of altering separation between electrode and nerve  | 73 |
| Figure E.8 — Electrode Factor Multiplier  | 77 |
| Figure E.9 — Strength-duration curve for electric field square wave pulse, exponentially decaying pulse, sinewave                                 | 78 |
| Figure E.10 — Variation of internal electric field (peak) sensitivity threshold with frequency  | 79 |
| Figure E.11 — ICNIRP 1998 and 2010 Basic Restrictions   | 80 |
| Figure E.12 — ICNIRP 2010 Occupational Basic Restriction  | 81 |
| Figure E.13 — Variation of maximum current with frequency, expressed as a ratio to the low frequency value for fully infiltrated fat              | 85 |
| Figure E.14 — Magnetic field assessment levels  | 88 |
| Figure E.15 — Voltages (rms) induced by magnetic field for the two assessment levels lines and three loop areas                                   | 89 |
| Figure E.16 — Electric field assessment levels  | 92 |
| Figure E.17 — Voltages (rms) induced by external electric field for the three reference levels and three electrode spacings                       | 93 |
| Figure E.18 — NSR for magnetic field exposure   | 95 |
| Figure E.19 — NSR for Electric Field exposure   | 96 |
| Figure E.20 — TDR for magnetic field exposure   | 98 |
| Figure E.21 — TDR for electric field exposure   | 99 |

## Tables

|  |    |
|--|----|
| Table 1 — Device parameters used for phase 2a and 2b assessments                         | 19 |
| Table 2 — Assessment levels  | 20 |
| Table 3 — Phase 2a assessment summary  | 26 |
| Table 4 — Description of exposure zones for phase 2b assessment procedure                | 28 |
| Table 5 — Applicable zone charts for bipolar stimulation                                 | 29 |
| Table 6 — Applicable zone charts for unipolar stimulation                                | 30 |
| Table 7 — Information necessary to proceed with phase 2c                                 | 39 |
| Table 8 — NSR modifiers for field levels in Zones 2b, 2c, or 2d                          | 41 |
| Table 9 — Example calculations for phase 2c assessment                                   | 41 |
| Table A.1 — Compliant workplaces and equipment with exceptions                           | 43 |
| Table C.1 — Summary of maximum values of key dimensions                                  | 51 |
| Table C.2 — Types of connection  | 53 |
| Table D.1 — Conductivity of fat and CSF from 50 kg pigs at selected frequencies          | 56 |
| Table D.2 — Measurements illustrating the variation of conductivity with age for pigs    | 56 |
| Table D.3 — Conductivity information required  | 59 |
| Table D.4 — Conductivities of fat in S/m   | 61 |
| Table D.5 — Conductivities in CSF in S/m   | 61 |
| Table D.6 — Cerebrospinal tissues: thickness and materials types                         | 62 |
| Table E.1 — Basic case parameters used in SENN model                                     | 71 |
| Table E.2 — ICNIRP 2010 Occupational Basic Restriction for <i>in situ</i> electric field | 81 |

|  |     |
|--|-----|
| Table E.3 — Multiplying factors for higher levels of stimulation .....   | 82  |
| Table E.4 — Maximum allowable electrode current for different electrode areas and averaging volumes<br>where $\sigma = 0.085 \text{ S/m}$ . (Values vary as $\sigma^{0.5}$ ) ..... | 84  |
| Table E.5 — Exposure Levels used for the assessments .....   | 87  |
| Table E.6 — Maximum NSR from magnetic field exposures .....  | 95  |
| Table E.7 — Maximum NSR from electric field exposures .....  | 97  |
| Table E.8 Maximum TDR from magnetic field exposures .....  | 98  |
| Table E.9 — Maximum TDR from electric field exposures .....  | 99  |
| Table E.10 — Overall assessment summary .....  | 100 |